• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Corcoran Gavin claimed ownership of 20 shares (SEC Form 3)

    4/2/25 4:31:50 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRCA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Corcoran Gavin

    (Last) (First) (Middle)
    C/O VERRICA PHARMACEUTICALS INC.
    44 W. GAY ST., SUITE 400

    (Street)
    WEST CHESTER PA 19380

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/31/2025
    3. Issuer Name and Ticker or Trading Symbol
    Verrica Pharmaceuticals Inc. [ VRCA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 20 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Christopher Hayes, Attormey-in-Fact 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VRCA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRCA

    DatePrice TargetRatingAnalyst
    11/6/2024Buy → Neutral
    H.C. Wainwright
    11/5/2024Outperform → Sector Perform
    RBC Capital Mkts
    7/25/2023$10.00Hold → Buy
    Needham
    3/22/2023$10.00Buy
    Jefferies
    2/13/2023$4.00 → $11.00Sector Perform → Outperform
    RBC Capital Mkts
    5/25/2022$16.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    3/10/2022$20.00Buy
    Brookline Capital
    3/3/2022$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $VRCA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Verrica Pharmaceuticals Inc.

    SCHEDULE 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    8/14/25 9:41:34 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Verrica Pharmaceuticals Inc.

    10-Q - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    8/12/25 4:20:52 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    8/12/25 4:11:09 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Nguyen Diem

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    6/9/25 4:45:16 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Corcoran Gavin

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    6/9/25 4:45:21 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Prygocki Mark A Sr

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    6/9/25 4:45:10 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Verrica Pharmaceuticals downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral

    11/6/24 6:25:52 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform

    11/5/24 6:29:20 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals upgraded by Needham with a new price target

    Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00

    7/25/23 7:35:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

    –   Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful End of Phase 2 Meeting for VP-315 for Basal Cell Carcinoma; Company is preparing for the Phase 3 program and exploring non-dilutive opportunities for financing further development – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases r

    8/12/25 4:01:00 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

    WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-267-6316 (domestic) or 1-203-518-9783 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the star

    8/6/25 7:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

    – Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand for YCANTH® in the second quarter of 2025, with 13,434 dispensed applicator units durin

    7/9/25 7:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stalfort John A Iii bought 1,123,595 shares and received a gift of 50,000 shares, increasing direct ownership by 168% to 1,873,800 units (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/26/24 4:15:08 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Rieger Jayson bought 280,898 shares and received a gift of 50,000 shares, increasing direct ownership by 60% to 882,826 units (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/26/24 4:15:13 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manning Paul B bought 22,921,348 shares and gifted 450,000 shares (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/26/24 4:15:07 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Financials

    Live finance-specific insights

    View All

    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

    WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-267-6316 (domestic) or 1-203-518-9783 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the star

    8/6/25 7:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

    WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

    5/7/25 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

    WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

    3/3/25 7:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Leadership Updates

    Live Leadership Updates

    View All

    Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

    – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

    11/4/24 4:05:00 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

    WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

    8/10/21 7:30:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

    Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

    7/9/21 7:30:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

    SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/26/24 4:15:26 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/14/24 9:32:46 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care